These drugs work to treat diabetes and weight loss by suppressing the appetite and lowering blood sugar and A1C—which may end up being an effective treatment for Alzheimer’s, heart conditions, depression, and many other conditions.
WeightWatchers’ bold gamble: CEO Sistani fuses AI, GLP-1 drugs, and 60 years of trust into a revolutionary health tech platform to conquer the $377B weight loss market.
A class of diabetes and weight loss drugs that includes Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could also help protect against a variety of cancers, according to new research published Friday, adding to mounting evidence that injections offer numerous additional health benefits as pressure builds for insurers and public health providers to cover the popular medication in spite of persistent shortages and cost concerns.
Novo Nordisk and Eli Lilly each have a higher market capitalization than Tesla, a dramatic shift from the end of 2021, when Tesla was worth four times more than each of the weight loss kingpins.